User menu

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

Bibliographic reference van der Holt, Bronno ; Löwenberg, Bob ; Burnett, Alan K ; Knauf, Wolfgang U ; Shepherd, John ; et. al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.. In: Blood, Vol. 106, no. 8, p. 2646-54 (2005)
Permanent URL http://hdl.handle.net/2078.1/26950